Actionable news
All posts from Actionable news
Actionable news in IBB: iShares NASDAQ Biotechnology Index Fund,

Juno's Cell-Therapy Fallout Keeps Growing

Juno is still in damage-control mode after Thursday's news the FDA had halted a clinical trial of its lead cancer treatment after three patient deaths. The treatment, a so-called cell therapy, uses a patient's own modified immune cells to fight a form of leukemia.

Juno blamed a change in a pre-treatment chemotherapy regimen for the deaths and said it hopes undoing that change will get the trial back up and running again quickly. But there's been fundamental damage to confidence in the company's stock and science. It has an uphill road to recovery.